COSCIENS Biopharma Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anna Elizabeth Biehn
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 222 Bay Street Toronto ON Canada M5K 1E7
- IPO Date
- Jul 18, 1996
- CIK
- 0001113423
- Website
- cosciensbio.com
- Similar Companies
- Business
- COSCIENS Biopharma Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel therapeutics for autoimmune and inflammatory diseases. The company primarily develops drug candidates targeting key immunological pathways with a focus on small molecule and biologic therapies; its pipeline includes promising candidates for diseases such as multiple sclerosis, lupus, and inflammatory bowel disease. COSCIENS Biopharma's product offerings include proprietary investigational drugs designed to modulate immune system activity and improve patient outcomes. Founded in 2014, the company is headquartered in Montreal, Canada, and operates with a focus on global clinical development and commercialization strategies. In terms of recent developments, COSCIENS Biopharma has expanded its strategic collaborations in 2024-2025, entering partnerships to accelerate clinical trials and enhance drug development capabilities. The company has also secured additional financing rounds to support its late-stage clinical programs and extend its pipeline development. Operationally, COSCIENS has advanced its lead drug candidates into Phase 3 clinical trials and expanded research into new therapeutic areas within immunology. These advances highlight the firm's commitment to growing its footprint in the biopharma industry while advancing innovative treatments for autoimmune and inflammatory diseases. COSCIENS Biopharma serves healthcare providers, pharmaceutical companies, and patients globally, with activities spanning North America, Europe, and select Asian markets. Its business segments include drug discovery, clinical development, and strategic commercialization partnerships. The company maintains a robust R&D infrastructure supported by collaborations with key research institutions and industry partners, enabling it to pursue precision medicine approaches. COSCIENS operates as a publicly traded entity under the ticker symbol CSCI. This comprehensive profile reflects COSCIENS Biopharma's core products and recent strategic initiatives, underscoring its role as an emerging biopharmaceutical player specializing in immune-related therapeutic areas with ongoing clinical advancements and growth-driven partnerships.
COSCIENS Biopharma Inc. Completes Share Capital Amendment
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
CSCI Leverages Technology, Workforce Expansion, and Operational Discipline to Drive Continued Growth Across Florida
COSCIENS Biopharma Inc. Reports Q1 2026 Results
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
COSCIENS Comments on Unusual Market Activity
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
COSCIENS Provides Strategic Update
Meet CSCI: The First Family of Florida Shell Construction
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
Fueled by Precision and Performance, President Daniel Goldburg Leads CSCI Into Its Next Chapter as Florida's Premier Structural Shell Contractor
COSCIENS Biopharma Inc. Announces Leadership Change
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents